News|Articles|August 1, 2001

Pharmaceutical Technology

  • Pharmaceutical Technology-08-01-2001
  • Volume 2001 Supplement
  • Issue 2

Stakes Rise for Blown Batches

Author(s)Jim Miller

The vulnerability of both the sponsors and the contractors has increased tremendously.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.